BCLI Annual CFI
$2.19 M
+$1.20 M+119.74%
31 December 2023
Summary:
As of January 19, 2025, BCLI annual cash flow from investing activities is $2.19 million, with the most recent change of +$1.20 million (+119.74%) on December 31, 2023. During the last 3 years, it has risen by +$6.64 million (+149.26%). BCLI annual CFI is now -63.31% below its all-time high of $5.98 million, reached on December 31, 2016.BCLI Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCLI Quarterly CFI
$0.00
$0.000.00%
30 September 2024
Summary:
As of January 19, 2025, BCLI quarterly cash flow from investing activities is $0.00, unchanged on September 30, 2024. Over the past year, it has stayed the same.BCLI quarterly CFI is now -100.00% below its all-time high of $6.78 million, reached on June 30, 2017.BCLI Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCLI TTM CFI
$196.00 K
+$12.00 K+6.52%
30 September 2024
Summary:
As of January 19, 2025, BCLI TTM cash flow from investing activities is $196.00 thousand, with the most recent change of +$12.00 thousand (+6.52%) on September 30, 2024. Over the past year, it has increased by +$12.00 thousand (+6.52%). BCLI TTM CFI is now -98.55% below its all-time high of $13.47 million, reached on June 30, 2019.BCLI TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCLI Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +119.7% | 0.0% | +6.5% |
| 3 y3 years | +149.3% | 0.0% | +6.5% |
| 5 y5 years | +280.1% | 0.0% | +6.5% |
BCLI Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +579.0% | -100.0% | +100.0% | -93.5% | +114.7% |
| 5 y | 5-year | -61.0% | +149.3% | -100.0% | +100.0% | -96.5% | +104.4% |
| alltime | all time | -63.3% | +119.4% | -100.0% | +100.0% | -98.5% | +101.1% |
Brainstorm Cell Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $0.00(0.0%) | $196.00 K(+6.5%) |
| June 2024 | - | $0.00(0.0%) | $184.00 K(-2.1%) |
| Mar 2024 | - | $0.00(-100.0%) | $188.00 K(-91.4%) |
| Dec 2023 | $2.19 M(+119.7%) | $196.00 K(-1733.3%) | $2.19 M(-27.7%) |
| Sept 2023 | - | -$12.00 K(-400.0%) | $3.04 M(-0.0%) |
| June 2023 | - | $4000.00(-99.8%) | $3.04 M(+0.5%) |
| Mar 2023 | - | $2.00 M(+93.2%) | $3.02 M(+202.6%) |
| Dec 2022 | $998.00 K(+209.0%) | $1.04 M(-9536.4%) | $998.00 K(-174.6%) |
| Sept 2022 | - | -$11.00 K(-8.3%) | -$1.34 M(-461.4%) |
| June 2022 | - | -$12.00 K(-29.4%) | $370.00 K(+7.9%) |
| Mar 2022 | - | -$17.00 K(-98.7%) | $343.00 K(+6.2%) |
| Dec 2021 | $323.00 K(-107.3%) | -$1.30 M(-176.5%) | $323.00 K(-75.5%) |
| Sept 2021 | - | $1.70 M(-4448.7%) | $1.32 M(-384.1%) |
| June 2021 | - | -$39.00 K(+5.4%) | -$464.00 K(-81.4%) |
| Mar 2021 | - | -$37.00 K(-87.7%) | -$2.50 M(-44.0%) |
| Dec 2020 | -$4.45 M(-179.3%) | -$302.00 K(+251.2%) | -$4.45 M(-1.0%) |
| Sept 2020 | - | -$86.00 K(-95.8%) | -$4.50 M(+51.3%) |
| June 2020 | - | -$2.07 M(+3.8%) | -$2.97 M(-704.9%) |
| Mar 2020 | - | -$1.99 M(+478.0%) | $491.00 K(-91.3%) |
| Dec 2019 | $5.62 M(-561.1%) | -$345.00 K(-124.0%) | $5.62 M(-43.4%) |
| Sept 2019 | - | $1.44 M(+3.5%) | $9.93 M(-26.3%) |
| June 2019 | - | $1.39 M(-55.6%) | $13.47 M(-1516.7%) |
| Mar 2019 | - | $3.13 M(-21.1%) | -$951.00 K(-21.9%) |
| Dec 2018 | -$1.22 M(-130.6%) | $3.97 M(-20.4%) | -$1.22 M(-50.1%) |
| Sept 2018 | - | $4.98 M(-138.2%) | -$2.44 M(-83.4%) |
| June 2018 | - | -$13.03 M(-555.1%) | -$14.66 M(-384.6%) |
| Mar 2018 | - | $2.86 M(+4.3%) | $5.15 M(+29.2%) |
| Dec 2017 | $3.99 M(-33.3%) | $2.75 M(-137.9%) | $3.99 M(+96.5%) |
| Sept 2017 | - | -$7.24 M(-206.8%) | $2.03 M(-78.8%) |
| June 2017 | - | $6.78 M(+299.1%) | $9.55 M(+228.3%) |
| Mar 2017 | - | $1.70 M(+115.6%) | $2.91 M(-51.3%) |
| Dec 2016 | $5.98 M(-153.0%) | $788.00 K(+175.5%) | $5.98 M(-1.8%) |
| Sept 2016 | - | $286.00 K(+108.8%) | $6.09 M(-21.4%) |
| June 2016 | - | $137.00 K(-97.1%) | $7.74 M(+9.8%) |
| Mar 2016 | - | $4.77 M(+430.7%) | $7.05 M(-162.5%) |
| Dec 2015 | -$11.28 M(+153.6%) | $898.00 K(-53.7%) | -$11.28 M(-24.5%) |
| Sept 2015 | - | $1.94 M(-449.4%) | -$14.94 M(-19.2%) |
| June 2015 | - | -$555.00 K(-95.9%) | -$18.48 M(+3.1%) |
| Mar 2015 | - | -$13.56 M(+392.0%) | -$17.93 M(+302.9%) |
| Dec 2014 | -$4.45 M(-267.5%) | -$2.76 M(+71.7%) | -$4.45 M(-244.1%) |
| Sept 2014 | - | -$1.61 M(>+9900.0%) | $3.09 M(+86.6%) |
| June 2014 | - | -$2000.00(-97.6%) | $1.66 M(+3.4%) |
| Mar 2014 | - | -$85.00 K(-101.8%) | $1.60 M(-39.8%) |
| Dec 2013 | $2.66 M | $4.78 M(-257.3%) | $2.66 M(-154.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2013 | - | -$3.04 M(+5231.6%) | -$4.89 M(+162.2%) |
| June 2013 | - | -$57.00 K(-105.9%) | -$1.86 M(+2.6%) |
| Mar 2013 | - | $971.00 K(-135.1%) | -$1.82 M(-36.0%) |
| Dec 2012 | -$2.84 M(+4337.5%) | -$2.77 M(>+9900.0%) | -$2.84 M(+2953.8%) |
| Sept 2012 | - | -$14.00 K(+55.6%) | -$93.00 K(+16.3%) |
| June 2012 | - | -$9000.00(-82.7%) | -$80.00 K(0.0%) |
| Mar 2012 | - | -$52.00 K(+188.9%) | -$80.00 K(+25.0%) |
| Dec 2011 | -$64.00 K(-6500.0%) | -$18.00 K(+1700.0%) | -$64.00 K(+48.8%) |
| Sept 2011 | - | -$1000.00(-88.9%) | -$43.00 K(-2.3%) |
| June 2011 | - | -$9000.00(-75.0%) | -$44.00 K(+41.9%) |
| Mar 2011 | - | -$36.00 K(-1300.0%) | -$31.00 K(-3200.0%) |
| Dec 2010 | $1000.00(-97.4%) | $3000.00(-250.0%) | $1000.00(-97.0%) |
| Sept 2010 | - | -$2000.00(-150.0%) | $33.00 K(-2.9%) |
| June 2010 | - | $4000.00(-200.0%) | $34.00 K(+13.3%) |
| Mar 2010 | - | -$4000.00(-111.4%) | $30.00 K(-23.1%) |
| Dec 2009 | $39.00 K(-125.0%) | $35.00 K(-3600.0%) | $39.00 K(+550.0%) |
| Sept 2009 | - | -$1000.00(<-9900.0%) | $6000.00(0.0%) |
| June 2009 | - | $0.00(-100.0%) | $6000.00(-53.8%) |
| Mar 2009 | - | $5000.00(+150.0%) | $13.00 K(-108.3%) |
| Dec 2008 | -$156.00 K(-55.0%) | $2000.00(-300.0%) | -$156.00 K(-58.1%) |
| Sept 2008 | - | -$1000.00(-114.3%) | -$372.00 K(-20.0%) |
| June 2008 | - | $7000.00(-104.3%) | -$465.00 K(-0.8%) |
| Mar 2008 | - | -$164.00 K(-23.4%) | -$468.70 K(+35.1%) |
| Dec 2007 | -$347.00 K(+139.3%) | -$214.00 K(+127.7%) | -$347.00 K(+160.9%) |
| Sept 2007 | - | -$94.00 K(-2948.5%) | -$133.00 K(-2.9%) |
| June 2007 | - | $3300.00(-107.8%) | -$137.00 K(-5.7%) |
| Mar 2007 | - | -$42.30 K(-56.8%) | -$145.30 K(+68.8%) |
| Dec 2006 | -$145.00 K(-30.9%) | - | - |
| Sept 2006 | - | -$98.00 K(+1860.0%) | -$86.10 K(+174.2%) |
| June 2006 | - | -$5000.00(0.0%) | -$31.40 K(-85.0%) |
| Mar 2006 | - | -$5000.00(-122.8%) | -$209.90 K(-55.1%) |
| Mar 2006 | -$209.90 K(-20.6%) | - | - |
| Dec 2005 | - | $21.90 K(-150.6%) | -$467.70 K(-4.8%) |
| Sept 2005 | - | -$43.30 K(-76.4%) | -$491.10 K(+9.7%) |
| June 2005 | - | -$183.50 K(-30.2%) | -$447.80 K(+69.4%) |
| Mar 2005 | -$264.30 K(<-9900.0%) | -$262.80 K(>+9900.0%) | -$264.30 K(>+9900.0%) |
| Dec 2004 | - | -$1500.00(<-9900.0%) | -$1500.00(<-9900.0%) |
| Sept 2004 | - | $0.00(0.0%) | $0.00(0.0%) |
| June 2004 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2004 | $0.00(0.0%) | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2003 | - | $0.00(0.0%) | $0.00(0.0%) |
| Sept 2003 | - | $0.00(0.0%) | $0.00(0.0%) |
| June 2003 | - | $0.00 | $0.00 |
| Mar 2003 | $0.00 | - | - |
FAQ
- What is Brainstorm Cell Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics annual CFI year-on-year change?
- What is Brainstorm Cell Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics quarterly CFI year-on-year change?
- What is Brainstorm Cell Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics TTM CFI year-on-year change?
What is Brainstorm Cell Therapeutics annual cash flow from investing activities?
The current annual CFI of BCLI is $2.19 M
What is the all time high annual CFI for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high annual cash flow from investing activities is $5.98 M
What is Brainstorm Cell Therapeutics annual CFI year-on-year change?
Over the past year, BCLI annual cash flow from investing activities has changed by +$1.20 M (+119.74%)
What is Brainstorm Cell Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of BCLI is $0.00
What is the all time high quarterly CFI for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high quarterly cash flow from investing activities is $6.78 M
What is Brainstorm Cell Therapeutics quarterly CFI year-on-year change?
Over the past year, BCLI quarterly cash flow from investing activities has changed by $0.00 (0.00%)
What is Brainstorm Cell Therapeutics TTM cash flow from investing activities?
The current TTM CFI of BCLI is $196.00 K
What is the all time high TTM CFI for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high TTM cash flow from investing activities is $13.47 M
What is Brainstorm Cell Therapeutics TTM CFI year-on-year change?
Over the past year, BCLI TTM cash flow from investing activities has changed by +$12.00 K (+6.52%)